Human bispecific EGFRvIII and CD3 antibody engaging molecules

US10053514B2 · kind B2 · utility

Assignees

• Duke University · US
• The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health · US

Inventors

• Darell Bigner · Mebane, US
• John H. Sampson · Durham, US
• Chien-Tsun Kuan · Cary, US
• Mingqing Cai · Durham, US
• Bryan Choi · Boston, US
• Patrick C. Gedeon · Durham, US
• Ira H. Pastan · Potomac, US

Key dates

• Filing date: Jul 9, 2014
• Grant date: Aug 21, 2018
• Expiry date: Jul 12, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/73
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are therapeutic agents.